Comparative Pharmacology
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus LARGON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOTIFEN FUMARATE versus LARGON.
KETOTIFEN FUMARATE vs LARGON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
Propionazine is a phenothiazine derivative that acts as a central dopamine receptor antagonist, particularly at D2 receptors. It also exhibits antihistaminergic, anticholinergic, and sedative effects by blocking histamine H1 and muscarinic receptors.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
50 mg intramuscularly every 4-6 hours as needed for nausea and vomiting. Maximum: 300 mg/day.
None Documented
None Documented
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Terminal elimination half-life is 20-30 hours in healthy adults, extending up to 40-60 hours in patients with hepatic impairment or elderly.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Primarily renal (approximately 50-80% as unchanged drug and metabolites) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (~10-15%).
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine